Flexion Therapeutics on Friday earned Food and Drug Administration approval for Zilretta, an extended-release treatment for osteoarthritis knee pain.
Here are three things to know.
1. Zilretta is administered as an intra-articular injection.
2. The non-opioid drug is intended to provide pain relief for patients with moderate to severe OA knee pain over a 12-week period.
3. Flexion expects Zilretta to hit the market by the end of the month.